Revolution Medicines’ Daraxonrasib Doubles Survival in Pancreatic Cancer Phase 3 Trial

Revolution Medicines announced that its experimental drug daraxonrasib demonstrated a significant survival benefit in a Phase 3 clinical trial for patients with previously treated metastatic pancreatic adenocarcinoma.

Patients receiving daraxonrasib lived a median of 13.2 months compared to 6.7 months for those receiving standard chemotherapy, representing an increase of 6.5 months in overall survival.

The drug, a daily oral pill, met all primary and secondary endpoints in the trial and reduced the risk of death by 60% versus chemotherapy, according to the company.

Revolution Medicines plans to submit the trial data to the U.S. Food and Drug Administration for approval and intends to use a Commissioner’s National Priority Voucher, which could enable a faster review process.

The company emphasized that daraxonrasib broadly targets RAS mutations, which are present in approximately 90% of pancreatic cancer cases and have historically been considered difficult to drug.

Pancreatic cancer remains one of the most lethal major cancers, with a five-year survival rate of just 13%, underscoring the urgent need for more effective treatment options.

Results from the trial were shared by Revolution Medicines on April 13, 2026, and reported by STAT News in an article published on April 17, 2026, which included insights from Paul Oberstein of NYU Langone’s Perlmutter Cancer Center, an investigator in the study.